Please login to the form below
Chloroquine
This page shows the latest Chloroquine news and features for those working in and with pharma, biotech and healthcare.
FDA grants emergency authorisation to chloroquine for COVID-19
outcomes. The results also demonstrated that 65 of the 80 patients receiving chloroquine treatment improved and were discharged from hospital in an average of less than five days. ... However, the investigation of hydroxychloroquine as a treatment for
Latest news
-
Novartis donates malaria drug for COVID-19 clinical trials
Hydroxychloroquine is a derivative of chloroquine, and is less toxic form of the latter drug. ... Chloroquine was first discovered in 1934, and is currently on the WHO’s list of essential medicines, and is readily available in generic form.
-
FDA maintains COVID-19 therapeutics must meet a ‘gold standard’
It said that it is already working closely with other government agencies and academic institutions that are evaluating the efficacy of the drug chloroquine, which is already approved for use against ... We will take all steps to ensure chloroquine
-
Trump calls on FDA to cut ‘red tape’ as coronavirus drug trials gather pace
Drug news round-up. The comments came amid a number of developments in among COVID-19 drug therapies, notably early data suggesting that an old malaria drug – chloroquine and its derivative
-
GSK cues up regulatory filings for relapsing malaria drug
In the DETECTIVE trial, 60% of patients on tafenoquine plus chloroquine were relapse-free over a six-month follow-up period, compared to 26% of the placebo plus chloroquine group. ... A third arm received the standard primaquine plus chloroquine regimen,
-
MERS-CoV deaths rise with few drugs in pipeline
There is some evidence to suggest existing drugs such as interferon/ribavirin, the HIV therapy lopinavir, antimalarials chloroquine and chlorpromazine and diarrhoea therapy loperamide might be re-purposed to have some
More from news
Approximately 2 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
As COVID-19 takes over the world, biopharma fights back
A standard malaria treatment: chloroquine and hydroxychloroquine. A decades-old antimalaria drug, chloroquine, entered the global spotlight in March after US President Donald Trump touted it as a potentially effective coronavirus ... treatment. Since then
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Amgen gets block on sales of Repatha rival in Germany
- Congress is in session – how companies are boosting their impact and engagement
- The state of pharma customer experience
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
